MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis

Maxime Liberelle1, Romain Magnez1, Xavier Thuru1

  • 1Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000, Lille, France.

Scientific Reports
|November 15, 2019
PubMed

Insights

We quantified the MUC4-ErbB2 interaction using MicroScale Thermophoresis (MST). This biophysical method determined the dissociation constants (Kd) for MUC4-ErbB2 complexes, aiding cancer drug discovery.

Area of Science:

  • Biophysics
  • Molecular Biology
  • Cancer Research

Background:

  • MUC4, a membrane mucin, promotes cancer cell proliferation and migration by interacting with the ErbB2 receptor.
  • MUC4 is a therapeutic target in pancreatic cancer due to its neoexpression in preneoplastic lesions.
  • The quantitative binding affinity of the MUC4-ErbB2 complex was previously unknown.

Purpose of the Study:

  • To characterize the MUC4-ErbB2 interaction using biophysical methods.
  • To determine the equilibrium dissociation constants (Kd) for MUC4-ErbB2 complexes.
  • To validate the role of MUC4's EGF domains in ErbB2 binding.

Main Methods:

  • MicroScale Thermophoresis (MST) was employed for quantitative protein interaction analysis.
  • Experiments utilized Chinese Hamster Ovary (CHO) cell lysates containing MUC4 variants (MUC4β and MUC4EGF3+1+2).
  • Equilibrium dissociation constants (Kd) were measured for MUC4-ErbB2 complexes.

Main Results:

  • The dissociation constants (Kd) for MUC4β-ErbB2 were determined to be 7-25 nM.
  • The dissociation constants (Kd) for MUC4EGF3+1+2/ErbB2 were found to be 65-79 nM.
  • The study confirmed that MUC4's three EGF domains are sufficient for efficient ErbB2 interaction.

Conclusions:

  • This research provides novel biophysical insights into the MUC4-ErbB2 interaction.
  • The findings support MUC4 as a target for cancer therapeutics, particularly in pancreatic cancer.
  • The MST approach is valuable for validating small molecule binding affinities in cancer drug discovery targeting MUC4-ErbB2.

Related Concept Videos